Literature DB >> 1353060

Analysis of the basis of resistance and susceptibility of CD4+ T cells to human immunodeficiency virus (HIV)-gp120 induced anergy.

A Faith1, R E O'Hehir, M Malkovsky, J R Lamb.   

Abstract

The resistance and susceptibility of T cells to human immunodeficiency virus (HIV)-gp120 induced anergy was examined. Antigen-dependent proliferation of polyclonal T cells was markedly inhibited by gp120, whereas from the analysis of monoclonal populations, T cells resistant to the effects of gp120 could be identified. Similarly, exposure of monoclonal T cells to gp120 in the absence of accessory cells, also demonstrated that some T cells could resist the induction of anergy. Loss of antigen recognition was associated with phenotypic modulation of CD3 and CD28, which was not observed in T cells resistant to functional inactivation by gp120. Modulation of CD4 was not related to induction of anergy in the monoclonal T cells examined in this study. Inhibition of T-cell responses by anti-CD4 antibodies was compared to that by gp120. Anti-CD4 antibodies, which cross-compete with gp120 for binding to CD4, inhibited the response to antigen of monoclonal T cells. In contrast, no tolerogenic signals were delivered by pretreating T cells with the anti-CD4 antibodies in the absence of accessory cells, indicating that inhibition was due to abrogation of the interaction of CD4 with major histocompatibility complex (MHC) class II molecules expressed on accessory cells. Although the free CD4-binding region peptide of gp120 could inhibit polyclonal T-cell responses, only the carrier-bound peptide was able to modulate cloned T cells, suggesting a conformational requirement for functional inactivation through engagement of CD4. The results reported here using clonal CD4+ T-cell populations demonstrate that effects of gp120 on antigen-dependent proliferation are not uniform, and that therapeutic intervention might be directed at T-cell populations identified as susceptible to HIV-gp120 induced anergy.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1353060      PMCID: PMC1421543     

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  30 in total

Review 1.  Adhesion receptors of the immune system.

Authors:  T A Springer
Journal:  Nature       Date:  1990-08-02       Impact factor: 49.962

2.  HIV-gp120 can block CD4-class II MHC-mediated adhesion.

Authors:  Y Rosenstein; S J Burakoff; S H Herrmann
Journal:  J Immunol       Date:  1990-01-15       Impact factor: 5.422

3.  Evidence for a physical association of CD4 and the CD3:alpha:beta T-cell receptor.

Authors:  K Saizawa; J Rojo; C A Janeway
Journal:  Nature       Date:  1987 Jul 16-22       Impact factor: 49.962

4.  Functional and phenotypic evidence for a selective loss of memory T cells in asymptomatic human immunodeficiency virus-infected men.

Authors:  C J van Noesel; R A Gruters; F G Terpstra; P T Schellekens; R A van Lier; F Miedema
Journal:  J Clin Invest       Date:  1990-07       Impact factor: 14.808

Review 5.  The CD4-gp120 interaction and AIDS pathogenesis.

Authors:  D J Capon; R H Ward
Journal:  Annu Rev Immunol       Date:  1991       Impact factor: 28.527

6.  Induction of specific clonal anergy in human T lymphocytes by Staphylococcus aureus enterotoxins.

Authors:  R E O'Hehir; J R Lamb
Journal:  Proc Natl Acad Sci U S A       Date:  1990-11       Impact factor: 11.205

7.  Human immunodeficiency virus-1 glycoproteins gp120 and gp160 specifically inhibit the CD3/T cell-antigen receptor phosphoinositide transduction pathway.

Authors:  D Cefai; P Debre; M Kaczorek; T Idziorek; B Autran; G Bismuth
Journal:  J Clin Invest       Date:  1990-12       Impact factor: 14.808

8.  HIV infection of H9 lymphoblastoid cells chronically activates the inositol polyphosphate pathway.

Authors:  K E Nye; A J Pinching
Journal:  AIDS       Date:  1990-01       Impact factor: 4.177

9.  Anti-CD4 mediates clonal anergy during transplantation tolerance induction.

Authors:  S E Alters; J A Shizuru; J Ackerman; D Grossman; K B Seydel; C G Fathman
Journal:  J Exp Med       Date:  1991-02-01       Impact factor: 14.307

10.  Novel anti-CD4 monoclonal antibodies separate human immunodeficiency virus infection and fusion of CD4+ cells from virus binding.

Authors:  D Healey; L Dianda; J P Moore; J S McDougal; M J Moore; P Estess; D Buck; P D Kwong; P C Beverley; Q J Sattentau
Journal:  J Exp Med       Date:  1990-10-01       Impact factor: 14.307

View more
  4 in total

1.  TLR7 induces anergy in human CD4(+) T cells.

Authors:  Margarita Dominguez-Villar; Anne-Sophie Gautron; Marine de Marcken; Marla J Keller; David A Hafler
Journal:  Nat Immunol       Date:  2014-11-17       Impact factor: 25.606

2.  Human immunodeficiency virus type 2 produces a defect in CD3-gamma gene transcripts similar to that observed for human immunodeficiency virus type 1.

Authors:  I Segura; C Delmelle-Wibaut; M Janssens; Y Cleuter; A van den Broeke; R Kettmann; K E Willard-Gallo
Journal:  J Virol       Date:  1999-06       Impact factor: 5.103

Review 3.  Interleukin-2 and human immunodeficiency virus infection: pathogenic mechanisms and potential for immunologic enhancement.

Authors:  A Kinter; A S Fauci
Journal:  Immunol Res       Date:  1996       Impact factor: 2.829

4.  Comprehensive sieve analysis of breakthrough HIV-1 sequences in the RV144 vaccine efficacy trial.

Authors:  Paul T Edlefsen; Morgane Rolland; Tomer Hertz; Sodsai Tovanabutra; Andrew J Gartland; Allan C deCamp; Craig A Magaret; Hasan Ahmed; Raphael Gottardo; Michal Juraska; Connor McCoy; Brendan B Larsen; Eric Sanders-Buell; Chris Carrico; Sergey Menis; Gustavo H Kijak; Meera Bose; Miguel A Arroyo; Robert J O'Connell; Sorachai Nitayaphan; Punnee Pitisuttithum; Jaranit Kaewkungwal; Supachai Rerks-Ngarm; Merlin L Robb; Tatsiana Kirys; Ivelin S Georgiev; Peter D Kwong; Konrad Scheffler; Sergei L Kosakovsky Pond; Jonathan M Carlson; Nelson L Michael; William R Schief; James I Mullins; Jerome H Kim; Peter B Gilbert
Journal:  PLoS Comput Biol       Date:  2015-02-03       Impact factor: 4.475

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.